Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 23;6(12):823–832. doi: 10.1002/psp4.12259

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Relationships between changes in covariates and the effects of meloxicam. The graphs show the impacts of lean body mass (a, b) and CYP2C9 genotypes (c, d) on plasma meloxicam concentrations and percent serum thromboxane B₂ (TXB₂) generation relative to basal value‐time profiles. The simulation was performed by varying CYP2C9 genotypes or lean body mass for 7.5‐mg daily meloxicam administration under steady‐state conditions. a and b, CYP2C9 *1/*1 genotype; c and d, the lean body mass is 55.0 kg.